$2.11
-4.5%Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
No Investing Cash Flow Data
ACTU has not reported any investing cash flow values in the available annual periods.
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
Steady FCF growth indicates consistent cash generation improvement. On a positive trajectory.
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
ACTU • NASDAQ
| Actuate Therapeutics Inc Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
OPERATING ACTIVITIES | ||||
-22.2M | -27.3M | -24.7M | -20.2M | |
6M | 2M | 423.5K | 654.1K | |
20.3K | 2.3M | 123.5K | -20.4K | |
(0.0) | (800.0) | (0.0) | (0.0) | |
-3M | 1.1M | 2.6M | 1.7M | |
-19.2M | -21.8M | -21.6M | -17.8M | |
INVESTING ACTIVITIES | ||||
FINANCING ACTIVITIES | ||||
24M | 24M | 0.0 | 0.0 | |
0.0 | 5.5M | 0.0 | 0.0 | |
-302.8K | -1.9M | 0.0 | 0.0 | |
23.7M | 27.5M | 4.1M | 19.3M | |
CASH FLOW SUMMARY | ||||
4.5M | 5.7M | -17.5M | 1.5M | |
8.6M | 3M | 20.4M | 19M | |
13.2M | 8.6M | 3M | 20.4M | |
-19.2M | -21.8M | -21.6M | -17.8M |
ACTU - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 22, 2026 | May 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 01, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 06, 2026 | May 21, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 28, 2025 | November 28, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 21, 2025 | November 21, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 13, 2025 | September 30, 2025 | 2025 |
Continue your ACTU research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.